In another strategy, nanoparticles such as FAP-targeted liposomes have been explored as carriers to specifically deliver therapeutic drugs (e.g., doxorubicin, anti-Tenascin C) to CAFs [155,156] or to remodel the tumor microenvironment [157,158]. The gene discussed is FAP; the disease is neoplasm.